Supernus Pharmaceuticals's total assets for Q3 2024 were $1.34B, an increase of 2.04% from the previous quarter. SUPN total liabilities were $335.55M for the fiscal quarter, a -6.37% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.